OGN vs. BBIO, APLS, MDGL, IONS, NUVL, ALPN, PRGO, ALKS, INSM, and BPMC
Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include BridgeBio Pharma (BBIO), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), Perrigo (PRGO), Alkermes (ALKS), Insmed (INSM), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
BridgeBio Pharma (NASDAQ:BBIO) and Organon & Co. (NYSE:OGN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership.
In the previous week, Organon & Co. had 6 more articles in the media than BridgeBio Pharma. MarketBeat recorded 11 mentions for Organon & Co. and 5 mentions for BridgeBio Pharma. Organon & Co.'s average media sentiment score of 0.76 beat BridgeBio Pharma's score of 0.63 indicating that BridgeBio Pharma is being referred to more favorably in the media.
Organon & Co. has a net margin of 16.50% compared to Organon & Co.'s net margin of -246.24%. Organon & Co.'s return on equity of 0.00% beat BridgeBio Pharma's return on equity.
Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
BridgeBio Pharma has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
BridgeBio Pharma presently has a consensus price target of $47.82, suggesting a potential upside of 62.37%. Organon & Co. has a consensus price target of $22.60, suggesting a potential upside of 8.13%. Given Organon & Co.'s stronger consensus rating and higher possible upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Organon & Co..
BridgeBio Pharma received 122 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 67.32% of users gave BridgeBio Pharma an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 28.5% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 1.2% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
BridgeBio Pharma beats Organon & Co. on 11 of the 18 factors compared between the two stocks.
Get Organon & Co. News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organon & Co. Competitors List
Related Companies and Tools
